The LXO Ambition

Since 2015, we have been specializing in the use of mature MAs in diverse therapeutic areas such as cardiology, central nervous system and internal medicine.and inter

A dynamic French pharmaceutical company with a human dimension, our growth is fuelled by the success of our brands, our international expansion and our strategy of external acquisitions. In a short period of 8 years, we have become one of the top third of French laboratories in terms of sales, and our ambition is to triple our sales within 5 years.

Laboratoire XO is also a committed laboratory:

We are committed to systematically favoring French or European production. In fact, 85% of our production is based in Europe, and 60% in France;

We are GDP-certified by ANSM, certified in Medical Visits and Ecocert-certified.

We entered a new phase of our growth in 2022 with the support of Stanley Capital. This European fund is committed alongside us to a dynamic acquisition strategy in Europe, with substantial additional financing already in place.